These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24528907)

  • 1. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
    Okon L; Rosenbach M; Krathen M; Rose M; Propert K; Okawa J; Werth V
    J Am Acad Dermatol; 2014 Mar; 70(3):583-4. PubMed ID: 24528907
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
    Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
    Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
    Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
    Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
    Wu EY; Schanberg LE; Wershba EC; Rabinovich CE
    Lupus; 2017 May; 26(6):646-649. PubMed ID: 27837194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
    Braunstein I; Goodman NG; Rosenbach M; Okawa J; Shah A; Krathen M; Kovarik CL; Luning Prak E; Werth VP
    J Am Acad Dermatol; 2012 Apr; 66(4):571-82. PubMed ID: 21821308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lenalidomide in refractory lupus pernio.
    Dalm VA; van Hagen PM
    JAMA Dermatol; 2013 Apr; 149(4):493-4. PubMed ID: 23715134
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
    Brunet-Possenti F; Hermine O; Marinho E; Crickx B; Descamps V
    J Am Acad Dermatol; 2013 Aug; 69(2):319-20. PubMed ID: 23866873
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
    Fennira F; Chasset F; Soubrier M; Cordel N; Petit A; Francès C
    J Am Acad Dermatol; 2016 Jun; 74(6):1248-51. PubMed ID: 27185425
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous lupus mucinosis successfully treated with systemic corticosteroid and systemic tacrolimus combination therapy.
    Sugiura K; Tanahashi K; Muro Y; Akiyama M
    J Am Acad Dermatol; 2013 Oct; 69(4):e200-2. PubMed ID: 24034403
    [No Abstract]   [Full Text] [Related]  

  • 10. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab.
    Kieu V; O'Brien T; Yap LM; Baker C; Foley P; Mason G; Prince HM; McCormack C
    Australas J Dermatol; 2009 Aug; 50(3):202-6. PubMed ID: 19659984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
    Yuki EFN; Silva CA; Aikawa NE; Romiti R; Heise CO; Bonfa E; Pasoto SG
    J Clin Rheumatol; 2021 Sep; 27(6):248-259. PubMed ID: 31693649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
    Reymann V; Bessis D; Bergeret B; Lipsker D; Du-Thanh A; Terrail N; Dandurand M; Dereure O
    J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):e113-e115. PubMed ID: 32730681
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study.
    Cesbron E; Bessis D; Jachiet M; Lipsker D; Cordel N; Bouaziz JD; Bagot M; Arnaud L; Barbaud A; Francès C; Chasset F;
    J Am Acad Dermatol; 2018 Jul; 79(1):162-165. PubMed ID: 29496481
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
    Wang X; Li M; Zeng X; Wang Q
    Rheumatology (Oxford); 2023 Oct; 62(10):e293-e294. PubMed ID: 36943383
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement.
    Hanjani NM; Nousari CH
    Arch Dermatol; 2002 Dec; 138(12):1616-8. PubMed ID: 12472362
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
    Sherman MA; Srinivasalu H; Kirkorian AY; Cardis MA
    Arthritis Rheumatol; 2023 Jan; 75(1):120. PubMed ID: 35997717
    [No Abstract]   [Full Text] [Related]  

  • 18. Lupus miliaris disseminatus faciei: treatment with the 1450-nm diode laser.
    Jih MH; Friedman PM; Kimyai-Asadi A; Friedman ES; Hymes SR; Goldberg LH
    Arch Dermatol; 2005 Feb; 141(2):143-5. PubMed ID: 15724009
    [No Abstract]   [Full Text] [Related]  

  • 19. Subacute cutaneous lupus erythematosus presenting in a child.
    Ciconte A; Mills AE; Shipley A; Marks R
    Australas J Dermatol; 2002 Feb; 43(1):62-4. PubMed ID: 11869212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model.
    Chan ES; Herlitz LC; Jabbari A
    J Invest Dermatol; 2015 Jul; 135(7):1912-1915. PubMed ID: 25789705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.